H. Lundbeck and Proximagen have formed a strategic CNS collaboration that is focused on developing three of Proximagen’s development programmes. Proximagen retains full ownership rights to these programmes but Lundbeck will receive certain rights to negotiate licences. As part of the agreement, Lundbeck will make a £10.3 M (US$16.1 M) equity investment in the UK biotech.